MSLN and cancer: Soluble Meso-TR3 targets the cancer biomarker MUC16 in vitro and in vivo and exhibits all the positive features of a traditional TRAIL-based cancer drug, as well as enhanced stability, enhanced killing capacity and favorable 1:3 stoichiometry of targeting (mesothelin) and effector domain (TR3).